Vecantoxatug Clinical TBD

Antibody Information

Entry ID	2905
INN	Vecantoxatug
Status	Clinical
Drug code(s)	GR2001
Brand name	None
mAb sequence source	mAb - source TBD
General Molecular Category	TBD
Format, general category	TBD
Format details	None
Isotype (Fc)	TBD
Light chain isotype	TBD
Linker	None
Ave. DAR	None
Conjugated/fused moiety	None
Discovery method/technology	None

Therapeutic information

Target(s)	Tetanus toxin
Indications of clinical studies	Tetanus prophylaxis
Primary therapeutic area	Infectious diseases

Development stage information

Phase lengths*

*The graph represents early-stage clinical development phase lengths. For molecules approved or under evaluation for marketing authorization in the US is provided a complete overview of all clinical development phase lengths. Phase lengths are calculated from the start of the first in human (FIH) study (Start of clinical phase). “Start of Phase 2” bar represents Phase 1 length (Start of clinical phase to start of Phase 2); “Start of Phase 3” bar represents Phase 1+2 length (Start of clinical phase to start of Phase 3); “Date BLA/NDA submitted” bar represents Phase 1+2+3 length (Start of clinical phase to Date BLA/NDA submitted); and “Date of first US approval” bar represents Phase 1 to first US approval length (Start of clinical phase to Date of first US approval).

Most advanced stage of development (global)	Phase 3
Status	Active
Start of clinical phase (IND filing or first Phase 1)	August 27, 2022
Start of Phase 2	March 15, 2023
Start of Phase 3	September 03, 2024
Date BLA/NDA submitted to FDA
Year of first approval (global)	None
Date of first US approval
INN, US product name	None
US or EU approved indications	None

Description/comment

Listed as mAbs in company pipeline (http://www.genrixbio.com/#/science?classId=class3)

Additional information

Anticipated events	None
Factor(s) contributing to discontinuation	None

Company	Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Licensee/Partner	None
Comments about company or candidate	Breakthrough Therapy designation in China. NCT06635798 CTR20243076 Phase 3 started in Sep 2024. NCT06302374 Phase 1/2 started in Mar 2023. CXSL2200485 has event date of Sep 27, 2022.
Full address of company	Shanghai, China Asia China https://synapse.patsnap.com/organization/575cf201cc223eac2f65ac65cddb2931